PDS Biotech announced publication of VERSATILE-002 results showing 39.3 months median overall survival, beating published benchmarks for HPV16-positive Head and Neck Cancer.
PDS Biotech announced publication of VERSATILE-002 results showing 39.3 months median overall survival, beating published benchmarks for HPV16-positive Head and Neck Cancer.